Sigilon Therapeutics, Inc. - FORM S-1MEF - EX-23.1 - EXHIBIT 23.1 - December 3, 2020

Attached files

file filename
S-1MEF - S-1MEF - Sigilon Therapeutics, Inc.tm2027374d9_s1mef.htm
EX-5.1 - EXHIBIT 5.1 - Sigilon Therapeutics, Inc.tm2027374d9_ex5-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated August 21, 2020, except for the effects of the reverse stock split discussed in Note 17 to the financial statements, as to which the date is November 30, 2020, relating to the financial statements, which appears in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-250070) of Sigilon Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-250070) incorporated by reference in this Registration Statement.

 

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

December 3, 2020